- Home
- Publications
- Publication Search
- Publication Details
Title
Glasdegib in newly diagnosed acute myeloid leukemia
Authors
Keywords
-
Journal
Expert Review of Anticancer Therapy
Volume -, Issue -, Pages 1-9
Publisher
Informa UK Limited
Online
2021-02-19
DOI
10.1080/14737140.2021.1891885
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Advances in the Treatment of Acute Myeloid Leukemia: New Drugs and New Challenges
- (2020) Nicholas J. Short et al. Cancer Discovery
- Venetoclax plus LDAC for patients with untreated AML ineligible for intensive chemotherapy: phase 3 randomized placebo-controlled trial
- (2020) Andrew Henry Wei et al. BLOOD
- Glasdegib (GLAS) plus low-dose cytarabine (LDAC) in AML or MDS: BRIGHT AML 1003 final report and four-year overall survival (OS) follow-up.
- (2020) Michael Heuser et al. JOURNAL OF CLINICAL ONCOLOGY
- Treatment of Acute Myeloid Leukemia in the Era of Genomics—Achievements and Persisting Challenges
- (2020) Steven D. Green et al. Frontiers in Genetics
- Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
- (2020) Courtney D. DiNardo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical outcomes of older patients with AML receiving hypomethylating agents: a large population-based study in the United States
- (2020) Amer M. Zeidan et al. Blood Advances
- Glasdegib as maintenance therapy for patients with AML and MDS patients at high risk for postallogeneic stem cell transplant relapse
- (2020) Andrew Kent et al. Blood Advances
- Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission
- (2020) Andrew H. Wei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study
- (2019) Andrew H. Wei et al. JOURNAL OF CLINICAL ONCOLOGY
- New drugs creating new challenges in acute myeloid leukemia
- (2019) Ing S. Tiong et al. GENES CHROMOSOMES & CANCER
- Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges
- (2019) Rory M. Shallis et al. BLOOD REVIEWS
- Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia
- (2019) Daniel A. Pollyea et al. LEUKEMIA
- Glasdegib plus intensive/nonintensive chemotherapy in untreated acute myeloid leukemia: BRIGHT AML 1019 Phase III trials
- (2019) Jorge E Cortes et al. Future Oncology
- Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia
- (2019) Gail J. Roboz et al. BLOOD
- Clonal Hematopoiesis and Evolution to Hematopoietic Malignancies
- (2018) Robert L. Bowman et al. Cell Stem Cell
- Phase Ib Study of Glasdegib, a Hedgehog Pathway Inhibitor, in Combination with Standard Chemotherapy in Patients with AML or High-Risk MDS
- (2018) Michael R. Savona et al. CLINICAL CANCER RESEARCH
- CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia
- (2018) Jeffrey E. Lancet et al. JOURNAL OF CLINICAL ONCOLOGY
- Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: Phase 2 study results
- (2018) Jorge E. Cortes et al. AMERICAN JOURNAL OF HEMATOLOGY
- Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia
- (2018) Courtney D. DiNardo et al. BLOOD
- Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome
- (2018) Jorge E. Cortes et al. LEUKEMIA
- Metabolism, excretion and pharmacokinetics of [14C]glasdegib (PF-04449913) in healthy volunteers following oral administration
- (2017) Justine L. Lam et al. XENOBIOTICA
- Targeting the PI3K/AKT pathway via GLI1 inhibition enhanced the drug sensitivity of acute myeloid leukemia cells
- (2017) Hui Liang et al. Scientific Reports
- Targeting GLI1 Suppresses Cell Growth and Enhances Chemosensitivity in CD34+ Enriched Acute Myeloid Leukemia Progenitor Cells
- (2016) Bing Long et al. CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
- Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial
- (2016) Sergio Amadori et al. JOURNAL OF CLINICAL ONCOLOGY
- Genomic Classification and Prognosis in Acute Myeloid Leukemia
- (2016) Elli Papaemmanuil et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia
- (2016) M. Konopleva et al. Cancer Discovery
- Characterization and prognostic features of secondary acute myeloid leukemia in a population-based setting: A report from the Swedish Acute Leukemia Registry
- (2015) Erik Hulegårdh et al. AMERICAN JOURNAL OF HEMATOLOGY
- International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
- (2015) H. Dombret et al. BLOOD
- Expression of Hedgehog Pathway Mediator GLI Represents a Negative Prognostic Marker in Human Acute Myeloid Leukemia and Its Inhibition Exerts Antileukemic Effects
- (2015) J. Wellbrock et al. CLINICAL CANCER RESEARCH
- Epidemiology and Clinical Significance of Secondary and Therapy-Related Acute Myeloid Leukemia: A National Population-Based Cohort Study
- (2015) Lene Sofie Granfeldt Østgård et al. JOURNAL OF CLINICAL ONCOLOGY
- The Hedgehog pathway as targetable vulnerability with 5-azacytidine in myelodysplastic syndrome and acute myeloid leukemia
- (2015) Raoul Tibes et al. Journal of Hematology & Oncology
- GLI2 inhibition abrogates human leukemia stem cell dormancy
- (2015) Anil Sadarangani et al. Journal of Translational Medicine
- Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial
- (2015) Michael R Migden et al. LANCET ONCOLOGY
- Acute Myeloid Leukemia
- (2015) Hartmut Döhner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Treatment with PF-04449913, an oral smoothened antagonist, in patients with myeloid malignancies: a phase 1 safety and pharmacokinetics study
- (2015) Giovanni Martinelli et al. Lancet Haematology
- Evaluation of the effect of food and ketoconazole on the pharmacokinetics of the smoothened inhibitor PF-04449913 in healthy volunteers
- (2014) M. Naveed Shaik et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A Phase I Study of PF-04449913, an Oral Hedgehog Inhibitor, in Patients with Advanced Solid Tumors
- (2014) A. J. Wagner et al. CLINICAL CANCER RESEARCH
- Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
- (2013) NEW ENGLAND JOURNAL OF MEDICINE
- Targeting hedgehog in hematologic malignancy
- (2012) D. A. Irvine et al. BLOOD
- The Origin and Evolution of Mutations in Acute Myeloid Leukemia
- (2012) John S. Welch et al. CELL
- Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia
- (2012) Hagop M. Kantarjian et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and Safety of Vismodegib in Advanced Basal-Cell Carcinoma
- (2012) Aleksandar Sekulic et al. NEW ENGLAND JOURNAL OF MEDICINE
- High-resolution array CGH identifies common mechanisms that drive embryonal rhabdomyosarcoma pathogenesis
- (2011) Vera Paulson et al. GENES CHROMOSOMES & CANCER
- Integrative Genomic Analysis of Medulloblastoma Identifies a Molecular Subgroup That Drives Poor Clinical Outcome
- (2010) Yoon-Jae Cho et al. JOURNAL OF CLINICAL ONCOLOGY
- Hedgehog signaling maintains chemoresistance in myeloid leukemic cells
- (2010) K C S Queiroz et al. ONCOGENE
- Drug resistance is dramatically restored by hedgehog inhibitors in CD34+ leukemic cells
- (2009) Masayoshi Kobune et al. CANCER SCIENCE
- Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia
- (2009) Chen Zhao et al. NATURE
- Expansion of Bcr-Abl-Positive Leukemic Stem Cells Is Dependent on Hedgehog Pathway Activation
- (2008) Christine Dierks et al. CANCER CELL
- Hedgehog: functions and mechanisms
- (2008) M. Varjosalo et al. GENES & DEVELOPMENT
- A paracrine requirement for hedgehog signalling in cancer
- (2008) Robert L. Yauch et al. NATURE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More